1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. DR. REDDY'S LABORATORIES LTD.
Dr. Reddy's Laboratories Ltd.
NSE: DRREDDY | BSE: 500124

Dr. Reddy's Labs Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 3 Starfolio Baskets
aboutDr. Reddy's Laboratories Ltd. is a global pharmaceutical company focused on providing affordable and innovative medicines. It operates through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and... Read More
US FDA InspectionsANDA Approvals
Ask AI about Dr. Reddy's Labs
1352.007.00(0.52%)

Near 52W High of ₹1414.90

2.0M
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
52.9 / 100
Mid-range PerformerThese stocks have average quality, financial and technical momentum, indicating a mid range performerView SimilarEmbed DVM
Analyst Price Target
-

19

S

11

W

9

O

3

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

10Positive13Negative

43.5%Pass in checklist

045
55
100

PE Valuation Check

Right Now
Overvalued
-43.1%
1 Year Forward
Overvalued
-24.8%
INSIGHTDr. Reddy's Labs is overvalued at both current PE and future earnings estimates.

Dr. Reddy's Labs Stock Price Analysis

Day Price Range

0.5% 1 Day return
1352 (LTP)
1,3451,363.7
LowHigh

Week Price Range

10.0% 1 Week return
1352 (LTP)
1,2241,363.7
LowHigh

Month Price Range

8.0% 1 Month return
1352 (LTP)
1,167.21,363.7
LowHigh

52 Week Price Range

12.5% 1 Year return
1352 (LTP)
1,1011,414.9
LowHigh
View full Price History/Seasonality

Dr. Reddy's Labs Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Dr. Reddy's Labs's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
51.4
AVG. ESTIMATE
44
LOW ESTIMATE
36.8
HIGH ESTIMATE
57.4
CURRENT EPS
AVG. ESTIMATE
Miss

EPS is expected to reduce by 14.4% in FY27

Consensus Recommendation

37 ANALYST Recommendations
BUY

The consensus recommendation from 37 analysts for Dr. Reddy's Labs is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Dr. Reddy's Labs Technical Analysis

Dr. Reddy's Labs EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1325.6
10 Day1296.2
12 Day1287.7
20 Day1263.5
26 Day1251.6
50 Day1230.2
100 Day1228.3
200 Day1237.4

Dr. Reddy's Labs Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202660.7%
Week42.8%
Month50.5%

Dr. Reddy's Labs Active Candlesticks

Gap Side By Side White Uptrend Advance Block Downtrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Dr. Reddy's Labs Resistance and Support

1353.57
Pivot
First Resistance1362.1
Second Resistance1372.3
Third Resistance1380.8
First Support1343.4
Second Support1334.9
Third Support1324.7
Day RSI75.3
Day MACD36.1
Day MFI79
Day MACD Signal Line23.6

Dr. Reddy's Labs Beta

1 Month0.8
1 Year0.5
3 Month0.7
3 Year0.5

Dr. Reddy's Labs Price Change Analysis

↑8%
Over 1 Month
LowHigh
1167.21363.7
↑18.1%
Over 3 Months
LowHigh
11301363.7
↑1.7%
Over 6 Months
LowHigh
11011414.9
↑12.5%
Over 1 Year
LowHigh
11011414.9
All Technicals →

Dr. Reddy's Labs Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Gvp Family TrustPromoter96,095,92011.5 %
Clearing MembersPublic4,605,2190.6 %
Life Insurance Corporation Of India P & Gs FundDii101,367,34312.1 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Dr. Reddy's Labs Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
KAPITALFORENINGEN PENSAM INVESTBlockSell09 Sep 20251250.60581,268NSE
KAPITALFORENINGEN INVESTIN PROBlockPurchase09 Sep 20251250.60581,268NSE
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828BlockSell14 Jul 20251254141,606NSE
THE MTBJ LTD. AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849BlockPurchase14 Jul 20251254141,606NSE
BOFA SECURITIES EUROPE SABlockSell26 Mar 20246184.85260,000BSE
BOFA SECURITIES EUROPE SABlockPurchase26 Mar 20246184.85260,000BSE
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITEDBlockSell18 Jan 20245645.4531,907BSE
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECTBlockPurchase18 Jan 20245645.4531,907BSE
AIA INVESTMENT TRUST AIA SINGAPORE PARTICIPATING FUND HERITAGE USDBlockSell26 Oct 20235355.20836BSE
AIA INVESTMENT TRUST AIA SINGAPORE PARTICIPATING FUND USDBlockSell26 Oct 20235355.201,551BSE
All deals
All insider trades

Dr. Reddy's Labs Corporate Actions

Dr. Reddy's Labs Dividend history and yield

Dr. Reddy's Labs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Dr. Reddy's Labs dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
110 Jul 2026
8FINAL10 Jul 2026Equity Share
210 Jul 2025
8FINAL10 Jul 2025Equity Share
316 Jul 2024
40FINAL-Equity Share
411 Jul 2023
40FINAL-Equity Share
511 Jul 2022
30FINAL-Equity Share

Dr. Reddy's Labs Bonus shares

Dr. Reddy's Labs bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
128 Aug 2006
1:129 Aug 2006

Dr. Reddy's Labs Board Meetings

Dr. Reddy's Labs past and upcoming board meetings.

#Ex-Date
PurposeNotes
123 Oct 2026
Quarterly Results-
222 Jul 2026
Quarterly Results-
312 May 2026
Audited Results-
421 Jan 2026
Quarterly Results-
524 Oct 2025
Quarterly Results-

Dr. Reddy's Labs Stock Split

Dr. Reddy's Labs stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
128 Oct 2024
5128 Oct 2024
210 Oct 2001
10525 Oct 2001
All Corporate Actions

Dr. Reddy's Labs Research Reports

Dr. Reddy's Labs research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
125 Oct 2026Deven Choksey
Target
14091229.5Accumulate14.6%9.96%pdf
224 Oct 2026ICICI Securities Limited
Reco
Target
14301229.5Buy16.31%9.96%pdf
323 Oct 2026Motilal Oswal11801229.5Neutral-4.03%9.96%pdf
423 Jul 2026Deven Choksey12911166.3Accumulate10.69%15.92%pdf
522 Jul 2026ICICI Direct13401166.3Buy14.89%15.92%pdf
All Reports of Dr.

Dr. Reddy's Labs Corporate Filings

Dr. Reddy's Labs BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Transcript of Earnings call
PDF
28 Oct 2026
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
PDF
24 Oct 2026
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement
PDF
24 Oct 2026
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of the Earnings call conducted on October 23, 2026
PDF
23 Oct 2026
Dr Reddys Laboratories Ltd - 500124 - General Update
Limited Review report of the Statutory Auditors on the Unaudited Financial results for the quarter and half year ended September 30, 2026 with UDIN
PDF
VIEW ALL

Dr. Reddy's Labs DocumentsAsk MarketMind AI

Dr. Reddy's Labs Earnings Call

Dr. Reddy's Labs earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
29 Oct 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseLink
24 Oct 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
28 Jul 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
15 Jul 2026Dr Reddys Laboratories Ltd - 500124 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Conference Call TranscriptLink
12 May 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseLink
view all

Dr. Reddy's Labs Annual Reports

Dr. Reddy's Labs financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Dr. Reddy's Labs Credit Ratings

Dr. Reddy's Labs credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
20 Jul 2026india ratingsIndia Ratings Rates Dr. Reddys Laboratories’ Additional and Affirms Existing Bank Loan Facilities at ‘IND AA+’/StableLink
29 Mar 2026india ratingsIndia Ratings Rates Dr. Reddys Laboratories’s Additional and Affirms Existing Bank Loan Facilities at ‘IND AA+’/StableLink
17 Feb 2026india ratingsIndia Ratings Affirms Dr. Reddy's Laboratories’s Bank Loan Facilities at ‘IND AA+’/Stable/‘IND A1+'Link
08 Jan 2026icra ratingsDr. Reddy’s Laboratories LimitedRating reaffirmedLink
26 Dec 2024icra ratingsDr. Reddy’s Laboratories LimitedRating reaffirmed; rated amount enhancedLink

Dr. Reddy's Labs Investor Presentations

Dr. Reddy's Labs investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
23 Oct 2026Dr Reddys Laboratories Ltd - 500124 - Copy Of Investor PresentationLink
22 Jul 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 May 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
12 May 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
21 Jan 2026Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Dr. Reddy's Labs - Company Profile

Dr. Reddy's Labs Management Structure

Dr. Reddy's Labs management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Erez IsraeliChief Executive Officer-Mar 26
Mr. Deepak SapraChief Executive Officer(API.,Services)-Mar 26
Mr. M V RamanaChief Executive Officer(Global Generics)-Mar 26
Mr. Krishna VenkateshGlobal Head(IPDO)-Mar 26
Mr. Patrick AghanianHead(Consumer Health Organisation)-Mar 26
Mr. Phanimitra BChief Information & Digital Officer-Mar 26
Mr. Sanjay SharmaChief Operating Officer-Mar 26
Mr. Milan KalawadiaChief Executive Officer-Mar 26
Mr. M V NarasimhamChief Financial Officer-Mar 26
K Randhir SinghCompany Secretary,Compliance Officer,Head(CSR)-Mar 26
Mr. M S Madhu SundarGlobal Head(Quality,PV)-Mar 26
Mr. Sandeep KhandelwalHead(Global Generics)-Mar 26
Sridevi KhambhampatyGlobal Head(Biologics),Senior Management Executive-Mar 26
Akhil RaviHead(API.),Senior Management Personnel-Mar 26

Dr. Reddy's Labs Board of Directors

Dr. Reddy's Labs Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
G V PrasadCo-Chairman & Managing Director1581.7Mar 26
Satish ReddyChairman & Exec. Director1006.6Mar 26
Leo PuriIndependent Non Exe. Director226.2Mar 26
Arun M. KumarIndependent Non Exe. Director221.4Mar 26
Pennv WanIndependent Non Exe. Director207.2Mar 26
Claudio AlbrechtIndependent Non Exe. Director202.4Mar 26
ALPNA HANSRAJ SETHIndependent Non Exe. Director197.7Mar 26
KODUMUDI PRANATHARTHIHARAN KRISHNANIndependent Non Exe. Director174Mar 26
Sanjiv MehtaIndependent Non Exe. Director174Mar 26
Shikha SharmaIndependent Non Exe. Director164.5Mar 26
Srikanth Ramakrishna VelamakanniIndependent Non Exe. Director-Mar 26
K Randhir SinghCS / CO / Head - CSR-Mar 26

Dr. Reddy's Labs Brands

Brands owned by Dr. Reddy's Labs

LOGOBRAND NAME
Cresp
Grafeel
PEG Grafeel
Reditux
LOGOBRAND NAME
Capibine
Cytogem
Dacotin
Docetere
LOGOBRAND NAME
Olsertain-AM
Olsertain-H
Optidoz
Plagril
LOGOBRAND NAME
Hydroheal-AM
Nexret
Niltan
Niltan-SPF
Website: www.drreddys.com

About the company - Business Profile

Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company focused on providing affordable and innovative medicines. It operates through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others (including Proprietary Products). The company holds a significant market position in the United States, India, and Emerging Markets, with a global reach extending to over 83 countries.

Key Points

  • Key Facts: Founded in 1984 and headquartered in Hyderabad, India. The company is listed on the NSE and BSE in India, and the NYSE in the United States. Its core offerings include generics, biosimilars, and active pharmaceutical ingredients (APIs).
  • Operations and Resources: As of FY2025, Dr. Reddy's operates 32 manufacturing and R&D facilities globally. In the U.S. market, it has a significant presence with 71 ANDAs and 2 NDAs pending approval, including 44 Para IV filings and 21 First-to-File (FTF) status products.
  • Market and Significance: The company serves major therapeutic areas, including gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. It is a key player in the U.S. generics market and maintains a strong rank in the Indian pharmaceutical market.
  • Revenue Breakdown (FY2025):
    • Global Generics: ₹285,453 million (approximately 87.9% of total revenue).
      • North America: ₹129,895 million (Growth: 28%).
      • India: ₹46,407 million.
      • Emerging Markets: ₹48,640 million (Growth: 7%).
      • Europe: ₹20,511 million (Growth: 17%).
    • PSAI: ₹29,801 million (approximately 10.7% of total revenue).
    • Others: ₹3,910 million (approximately 1.4% of total revenue).
  • Technological Advancements and Key Products:
    • Biosimilars: Filed a Biologics License Application (BLA) for abatacept biosimilar (IV presentation) for the U.S. market in December 2025. Received European Commission and UK MHRA approval for denosumab biosimilar.
    • Innovation: Launched Tegoprazan (PCAB) for acid-related gastrointestinal diseases and Linaclotide (Colozo) for chronic constipation.
    • Aurigene.AI: Utilizes an AI-assisted drug discovery platform in its CDMO business (Aurigene Pharmaceutical Services Limited).
  • Partnerships and Acquisitions:
    • Entered a non-binding strategic cooperation for Peptide APIs with Hybio Pharmaceutical.
    • Acquired a Nicotine Replacement Therapy (NRT) portfolio from Haleon, which contributed significantly to Europe's revenue growth (51% of segment revenue in Q3FY26).
    • Collaborated with Alvotech for biosimilar development and partnered with Unitaid and CHAI for HIV prevention tools (Lenacapavir).
  • Employee Count and Diversity: Employs over 26,000 individuals globally representing 57 nationalities. Gender diversity stood at 21.8% in FY2025.
  • Financial Performance (FY2025):
    • Total Revenue: ₹325,535 million.
    • Gross Profit: ₹190,428 million (58.5% margin).
    • EBITDA: ₹92,133 million (28.3% margin).
    • PAT: ₹56,544 million.
    • ROCE: 27.7%.
  • Strategic Initiatives: Focuses on strengthening the core business, advancing its biosimilar pipeline (e.g., Semaglutide, Abatacept), and augmenting growth through M&A and in-licensing. The company targets Carbon Neutrality (currently at 60% in FY2025) and increasing Renewable Power usage (currently 68%).

References

  1. Annual Report May 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Oct 2025
  4. Annual Report May 2024

Dr. Reddy's Labs FAQ

Dr. Reddy's Labs today is trading in the green, up by 0.52% at ₹1,352.
Dr. Reddy's Labs is currently trading up 0.52% on an intraday basis. In the past week the stock rose 9.96%. Stock has been up 18.1% in the past quarter and rose 12.46% in the past year. You can view this in the share price history/seasonality section.
Dr. Reddy's Labs is listed on NSE with the ticker DRREDDY and on BSE as 500124. It's currently trading on NSE at a share price of ₹1,352 and on BSE with a share price of ₹1,350.2.
The market cap of Dr. Reddy's Labs is ₹112,848.17 Cr. as of Oct 30, 2026.
Dr. Reddy's Labs announced a FINAL dividend of 800% which equals ₹8 in Jul 10, 2026.The last three ex-dates for Dr. Reddy's Labs were Jul 10, 2025, Jul 16, 2024 and Jul 11, 2023. To view the full dividend history of Dr. Reddy's Labs click here.
Dr. Reddy's Labs has undergone 2 stock splits and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Dr. Reddy's Labs stock split was on Oct 28, 2024 at a ratio of 5:1 and the last bonus share announcement was on Aug 28, 2006 at a ratio of 1:1.
Dr. Reddy's Labs reported ₹8,854 Cr. in revenue, ₹924.8 Cr. in net profit, and ₹1,886.8 Cr. in EBITD as of Oct 23, 2026 for Q2 FY26-27.
According to the predictions of 37 analysts, the share price prediction for Dr. Reddy's Labs is ₹1,358.95 with an upside of 1%.
The PE ratio of Dr. Reddy's Labs is 40.3 as of Oct 30, 2026.
The PB ratio of Dr. Reddy's Labs is 2.94 as of Oct 30, 2026.
You can view the latest analyst reports on the Dr. Reddy's Labs reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×